Understanding a clonoSEQ Report
Adaptive Biotechnologies delivers a report summarizing your clonoSEQ MRD results to your doctor to review along with clinical examination, your medical history, and other test results and findings.
Be sure to talk with your doctor about the optimal timing for clonoSEQ testing based on the type of blood cancer you have and your specific treatment plan.
References to “cancer” on this webpage refer specifically to CLL, multiple myeloma, and B-ALL. References to “sample” refer to bone marrow or blood from patients with CLL and bone marrow from patients with multiple myeloma or B-ALL. Talk to your doctor about your options if you have another type of blood cancer and are interested in MRD testing.
clonoSEQ reports include the following information:
clonoSEQ MRD Status
A positive (+) result means residual disease was detected. A negative (-) result means residual disease was not detected. Each report will provide your updated MRD status.* You can gain valuable insights about your cancer regardless of whether you have a positive or negative result.
Talk with your doctor about your clonoSEQ MRD status to better understand what a positive or negative result means for you and your treatment plan.
*False positive or false negative results may occur for reasons including, but not limited to: contamination, technical, and/or biological factors.
This is the amount of cancer-related cells detected in your sample. This number shows how much disease is present in your sample at that point in time. Your doctor can help put this number into context based on your current phase of treatment and therapeutic goals.
A simple graph will show any changes detected in your MRD level over time. Watching these changes will help you and your doctor better understand your response to treatment and track changes in your cancer over time.
This page is intended for a US-based audience.
clonoSEQ® is an FDA-cleared test used to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). IGHV testing is also available as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
clonoSEQ is only available by prescription from a licensed healthcare professional. Results may vary. Talk to your healthcare provider to see if clonoSEQ testing is right for you. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.